Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Not Applicable

Completed

• Conditions: Activating EGFR Gene Mutation Negative; Health Care Provider; Stage IVA Lung Cancer AJCC v8; Activating ROS1 Gene Mutation Negative; Activating ALK Gene Mutation Negative; Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
• Interventions: Other: Counseling; Other: Questionnaire Administration; Other: Medical Chart Review

• Registration Number: NCT03944265
• Lead Sponsor: Thomas Jefferson University

Brief Summary

This trial studies the use of genetics and shared decision making in improving care for patients with stage IVA-C non-small cell lung cancer. Developing educational tools may help patients with non-small cell lung cancer to increase patient treatment knowledge, reduce decisional conflict, and promote treatment shared decision making with their health care providers.

Detailed Description

PRIMARY OBJECTIVES:

I. Use the information on genomic tumor diagnostics, provider treatment recommendations, and patient and provider feedback on the treatment decision making process, which will be used to develop materials and methods to adapt an existing decision counseling program (DCP) for use with patients diagnosed with advanced non-small cell lung carcinoma (NSCLC) as a standard component of clinical care.

SECONDARY OBJECTIVES:

I. Pilot test the adapted DCP in a subset of patients to determine the feasibility of delivering the DCP session.

II. Assess DCP effects on patient treatment knowledge and decisional conflict. III. Assess treatment choice.

OUTLINE:

PHASE I: Use physician input to develop draft treatment education materials and use patient input to adapt an online decision counseling application for use in helping patients clarify treatment preference.

PHASE II: Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.

After completion of study, participants are followed up at 30 and 60 days.

Study Timeline

• Study Start: 2019-02-08
• Study First Submitted: 2019-04-24
• Study First Submitted QC: 2019-05-08
• Study First Posted: 2019-05-09
• Primary Completion: 2020-12-01
• Study Completion: 2020-12-31
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-28
• Last Update Posted: 2025-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Newly diagnosed with advanced NSCLC (stage IV a-c) that are wild-type for activating genetic alterations (EGFR, ROS 1, and ALK).
• May or may not be candidates for immune checkpoint therapy.
• May have had 1-any number of prior systemic therapy regimens.
• If prior systemic regimen, must have progression disease at time of evaluation.
• Untreated brain metastases permitted.
• Completed pathological analysis of tumor tissue.
• Patients who have exhausted targeting therapy options.
• Can speak and read English.
• All participants must be willing to comply with all study procedures and be available for the duration of the study.
• Providers: Those who treat NSCLC patients as described above.

Exclusion Criteria

• There are no specific exclusions in this trial for particular medical conditions, comorbidities, or performance status. Any patient deemed appropriate to be considered for evaluation and/or treatment would be appropriate to include in this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Supportive care (treatment decision counseling session)	Medical Chart Review	Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
Supportive care (treatment decision counseling session)	Counseling	Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
Supportive care (treatment decision counseling session)	Questionnaire Administration	Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.

Primary Outcome Measures

Name	Time	Method
Development of materials and methods to adapt an existing decision counseling program (DCP) for use with patients diagnosed with advanced non-small cell lung cancer as a standard component of clinical care	Up to 6 weeks	Results will be reported descriptively. A Decision Counseling Program (DCP) is a tool that allows patients and physicians to engage shared decision making. The DCP will be created based on genetic tumor diagnostics, provider treatment recommendations, and feedback from patients and providers gathered from interviews.

Secondary Outcome Measures

Name	Time	Method
Treatment choice of patients after receiving counseling	Up to 60 days	Results will be reported descriptively. Will be collected on pre and post surveys that will be completed by patients. Overall summary statistics will be computed for the patient surveys. Medical records data will be reviewed in order to determine the patient treatment regimen.
Feasibility of the adapted DCP in a subset of patients: proportion of consenting patients who complete the DCP	Up to 6 weeks	Results will be reported descriptively. The feasibility endpoint will be the proportion of consenting patients who complete the DCP, about which we will estimate an exact 95% confidence interval by the Clopper-Pearson method.
DCP effects on patient treatment knowledge and decisional conflict	Up to 60 days	Results will be reported descriptively on pre and post surveys that will be completed by patients Survey is the Decisional Conflict Scale (DCS) Total and subscores have applicable items are a) summed; b) divide by 10; and c) multiplied by 25 Total Score Items 1-10 Score range: 0 \[No decisional conflict\] to 100 \[extremely high decisional conflict\].; Uncertainty Sub score Items 9, 10 Score range: 0 \[feels extremely certain about best choice\] to 100 \[feels extremely uncertain about best choice\] Informed Sub score Items 1, 2, 3 Score range: 0 \[feels extremely informed\] to 100 \[feels extremely uninformed\].; Values Clarity Sub score Items 4, 5 Score range: 0 \[feels extremely clear about person; a values for benefits and risks/side effects\] to 100 \[feels extremely unclear about personal value\] Support Sub score Items 6, 7, 8 Score range: 0 \[feels extremely supported in decision making\] to 100 \[feels extremely unsupported in decision making\]

Trial Locations

Locations (1)

Sidney Kimmel Cancer Center at Thomas Jefferson University; 🇺🇸 Philadelphia, Pennsylvania, United States